key: cord-0040310-dng8ardh
authors: Lobeck, Lorri J.
title: Multiple Sclerosis
date: 2003-09-11
journal: Encyclopedia of the Human Brain
DOI: 10.1016/b0-12-227210-2/00224-7
sha: 06b5921438264fba1d88588b7b6c962e9ed7b7d2
doc_id: 40310
cord_uid: dng8ardh

nan

Lhermitte's phenomenon Tingling or electrical-type sensation experienced as a result of neck flexion, felt due to mechanosensitivity of demyelinated axons.

major histocompatibility complex An area on chromosome 6 that encodes immune response genes; possible area of genetic susceptibility in multiple sclerosis.

myelopathy Disease of the spinal cord, typically with weakness and/or sensory disturbance below the level of demyelination.

plaque Lesions of multiple sclerosis characterized pathologically by light gray to pink discoloration in white matter regions of the central nervous system.

relapse Neurologic signs or symptoms occurring in individuals with multiple sclerosis, persist for days to weeks, followed by partial or complete recovery.

Multiple sclerosis (MS) is an inflammatory, demyelinating disease of the central nervous system that results in destruction of both myelin and axons. The cause of the disease is unknown; however, it is believed to be an immune-mediated process. The disease is characterized by relapses and remissions of neurologic signs and symptoms early in the course, followed in some cases by progressive decline of neurologic function. Although most individuals are between 15 and 60 years of age at the time of diagnosis, the disease affects all age groups and causes varying levels of disability. Women are twice as likely to develop the disease as men.

An important feature of multiple sclerosis is the marked variability in neurologic symptoms and clinical course. Four different types of disease course have been described. Most patients present with relapsingremitting disease. An individual develops neurologic symptoms and signs over hours to days and typically recovers in 6-8 weeks. This is followed by various lengths of disease-free periods. Some individuals have few relapses and no residual symptoms, whereas others have frequent relapses and accumulating disability. Approximately one-half of the patients with relapsingremitting disease go on to develop secondary progressive disease. In this case, features of relapsingremitting disease are followed by a gradual decline in function with or without superimposed relapses. Primary progressive disease, which affects 10-15% of individuals with MS, is characterized by a gradual decline in neurologic condition from onset, without relapses. This form of disease progression is typically seen in older individuals, more often males, as a progressive myelopathy. A fourth type, progressive-relapsing MS, is similar to primary progressive MS but with superimposed relapses. The term benign MS is used carefully. Current estimates of disease that truly remains benign are lowF5-10% of all patients.

Based on epidemiologic and genetic data, MS is believed to be caused by some environmental agent that triggers the disease in susceptible individuals. The trigger is unknown but likely infectious. Advances in biotechnology and better trial design have led to new therapies that are at least partially effective in treating the disease.

There are an estimated 400,000 individuals in the United States who have MS and 1 million worldwide. The prevalence of the disease in individuals of Northern European descent is 1 in 1000, whereas in Asians the prevalance is 2 per 100,000. The highest prevalence rate is 250 cases per 100,000 individuals in the Orkney Islands, north of Scotland. Hispanic, Asian, and African Americans are less likely than Caucasians to have the disease. MS is usually sporadic, and often there is no documented family history. However, some families have shown an increased frequency of the disease and thus attention has focused on the genetic versus environmental features of the disease. The prevalence of MS varies along a north-south gradient worldwide, increasing as one moves away from the equator, even in countries with relatively homogenous racial populations. This gradient of disease prevalence suggests an environmental cause. There are exceptions to this pattern, such as Sicily and Malta, two areas in close proximity, which have a 10-fold difference in prevalence rate. Additionally, there are ethnic groups that appear resistant to the disease in high-risk areas, such as the Hutterites of western Canada and Native Americans in North America, reinforcing the genetic features of the disease. Furthermore, the north-south gradient may be explained by the migration pattern of ethnic groups, as they tended to migrate to similar climates. Studies of individuals moving from high-risk to low-risk areas after puberty show that these individuals carry the risk of the first location for developing MS, suggesting that an environmental factor may trigger the disease early in life. Clusters of cases of MS have been described, but many have not withstood further scrutiny to provide evidence that epidemics of MS occur. In summary, the data indicate that the geographical distribution of MS cannot be due to a single environmental factor, nor can genetic factors alone explain the distribution.

Epidemiologic studies provided early, albeit indirect, evidence of a genetic susceptibility toward developing MS. Studies of monozygotic twins illustrated a 25-30% lifetime risk of developing the disease if one sibling is effected. Dizygotic twins have a risk similar to that of their nontwin siblings (2-5%), which is higher than that for the normal population. Additional studies have shown that the risk is higher in full siblings rather than half-siblings. Siblings of individuals with MS raised in separate homes retain a higher risk of developing the disease. First-degree, adoptive, nonbiologic relatives do not have an increased risk compared to the general population; thus, genetic rather than environmental factors are more likely to explain familial clustering of disease. In the early 1970s, an association between the risk of developing MS and the major histocompatibility complex (MHC) on chromosome 6, which encodes immune response genes, was recognized. The MHC class I and class II molecules are glycoproteins located on a cell surface that present antigen to antigen-specific T cells. An individual's ability to react to an antigen is determined by the MHC region. CD8 + T cells interact with MHC class I molecules on the surface of all nucleated cells in humans; those molecules are known as human leukocyte antigens (HLA)-A, -B, or -C. Class II molecules are present on only some cells, including monocytes, macrophages, endothelial cells, and microglial cells. These antigens are described as HLA-DP, -DQ, and-DR. Although there may be a weak association with HLA-A3, multiple studies have shown an increased occurrence of HLA-DR2 haplotypes associated with MS. Most individuals with MS do not have this HLA-DR haplotype; thus, it is not essential or sufficient to cause the disease. It is also possible that an unidentified gene close to the HLA gene is the susceptibility locus. Recent genetic studies indicate that multiple unlinked genes may influence the risk for developing MS. Each gene may add to the risk. Different genes may influence susceptibility in some individuals and not others. A screen of the entire genome for regions related to risk of MS with anonymous genetic markers identified a susceptibility loci in the MHC region.

One model for MS in animals is experimental allergic encephalomyelitis (EAE). In this animal model, the susceptibility to developing demyelination is based on genetic risk. Specific chromosomes and segments have been identified in the animal model that increase the risk. The model suggests that initial events that occur in the disease may be mediated by different genetic factors than those that cause later progression of the disease.

The search for an infectious cause of MS has been pursued for many years. Bacteria, spirochetes, and atypical bacteria have be considered, although not confirmed. Viruses have been the focus of the search based on epidemiologic, genetic, pathologic, and serologic studies. The nonrandom North-South gradient of disease occurrence, described previously, is atypical for other autoimmune diseases and suggests the role of an environmental trigger. The low rate of concordance for monozygotic twins is evidence against MS being a purely genetic diseases. Because twins share many childhood diseases one would expect the concordance rate to be much higher if MS was a result of a nonspecific response to multiple agents. More likely, a specific, poorly transmissible agent leads to activation of the disease. Pathologic studies show that the changes seen in the central nervous system are similar in MS and viral illnesses. Both can produce inflammatory demyelinating lesions in the brain. Persistent viral infections can cause chronic demyelination.

Immunologic studies have noted the cerebrospinal fluid is similar in viral infections and MS. In viral infections, however, the oligoclonal bands can be identified as due to specific viral antigens. In MS, the oligoclonal bands are not known to react with a specific antigen. Antibodies are elevated in the cerebrospinal fluid and serum in patients with MS to such viruses as measles, Epstein-Barr virus, rubella, mumps, and herpes simplex, but this is more likely due to a nonspecific increase due to genetic or immunologic factors rather than a specific response to a virus.

There are animal models of viral demyelinating diseases, that resemble MS, including canine distemper virus, Theiler's murine encephalomyelitis, murine coronavirus, and visna. Furthermore, viruses are known to result in demyelinating diseases in humans. For example, postinfectious encephalomyelitis or acute disseminated encephalomyelitis (ADEM) have occurred following infection with measles, varicella, or Epstein-Barr virus. Persistent infections with papovavirus cause progressive multifocal leuko-encephalopathy (PML) in immunocompromised individuals.

Proposals to explain how viruses may cause MS include an immune system response to a chronic or transient virus, reactivation of a persistent infection, or viral infection of immunocompetent cells including lymphocytes. ''Molecular mimicry'' may explain the immune system response to virus, or other infectious agents. This model suggests that a viral peptide is similar to a component of myelin. The immune system recognizes the foreign viral peptide but cross-reacts with a myelin, resulting in activation of the immune system. Further damage results with exposure of additional myelin antigens. Exposure of antigens may result in epitope shifting, in which the initial inciting antigen no longer remains the sole perpetrator in the immune process. Some viruses (e.g., Epstein-Barr virus, cytomegalovirus, and measles) are known to have peptides that are similar to antigens identified on myelin components. Furthermore, the antigen may not be a component of myelin but an enzyme or regulatory protein, which may affect the immune function in other ways (e.g., permeability of the bloodbrain barrier or myelin metabolism). Superantigens, bacterial or viral envelope components that activate large populations of T cells or multiple clones of T cells, may be another mechanism by which a clone of auto reactive T cells may be activated. Others argue that a latent viral infection results in disease. Periodic relapses would be explained by reactivation of the virus. Progression may be due to failure of the host to inactivate the viruses. Several viruses are known to exist in the human central nervous system and to reactivate. For example, herpes zoster causes chicken pox in childhood and then reactives in the adult as shingles, a disease with rash in a dermatomal pattern. In other cases, a virus remains as a persistent infection. The measles virus causes subacute sclerosing panencephalitis. HIV infections result in various neurologic complications, including dementia. HTLV1 causes a progressive myelopathy. Whether the virus causes direct injury to neural tissue or causes bystander inflammation and demyelination is unknown. Finally, it is possible that viral infection of lymphocytes or other immune cells leads to changes in function of these cells and ultimately altered immunity.

Many viruses have been suggested as inciting agents for MS. Recently, there has been interest in human herpesvirus 6 (HHV-6). Most, if not all, types of herpes are latent in the nervous system. They are transported within axons and are known to cause demyelination. HHV-6 causes roseola or sixth disease in children, and like other herpesviruses it may reactivate in the adult nervous system. The presence of this virus has been confirmed in the brains of individuals with MS and others. Determination of the role of this virus in MS requires additional testing.

Most authorities believe the inflammatory, demyelinating disease process is immunemediated, even though the cause remains unknown. The target of inflammation may be a component of myelin. The process most likely begins with the T cell. Antimyelin T cells are recognized in the normal adult peripheral blood, but in MS these cells migrate to the central nervous system. Humeral immune responses are also likely, based on the intrathecal presence of immunoglobulins. The antigen recognized by these antibodies has not been determined. Myelin basic protein (MBP) and proteolipid protein make up 30-50% of myelin protein. Myelin oligodendroglia protein (MOG) makes up 50% of central nervous system myelin. This protein is not present in the peripheral nervous system and may be the antigen in this exclusively central nervous system disease. MOG is located on the oligodendroglia surface of the outer lamella of the myelin sheath and is thus accessible to attack. Other possible targets include myelin-associated glycoprotein, ab crystalline, 2-3-cyclic nucleotide, 3 0 -phosphodiesterase, and viral antigens.

The marmoset model of relapsing experimental allergic encephalomyelitis, which is histologically similar to MS, has demonstrated that T cells recognize MBP and MOG. These T cells induce inflammation, but demyelination does not occur unless the MOG antibody is present. Although MOG may be the initial antigen and inciting factor, exposure as a result of inflammation induces new antigens and epitope shifting. The antigen for this disease is difficult to identify possibly because there are multiple antigens. Figure 1 illustrates the proposed mechanisms for the immune-mediated injury in MS. Genetic or environmental factors (viruses, bacteria, or superantigens) cause activation of circulating T cells. Adhesion molecules on the circulating T cell surface, very late antigen (VLA-4) and lymphocyte function associated antigen (LFA-1), bind complementary receptors on the endothelium, intracellular cell adhesion molecule-1, and vascular cell adhesion molecule-1. Once in the central nervous system, the activated T cell secretes cytokines, including tumor necrosis factor-b (TNF-b) and interferon-g (IFN-g), which in turn activate antigen presenting cells (APCs) including astrocytes, macrophages, and microglia. Class II MCH molecules on APCs and T cells interact in the presence of central nervous system antigen. Costimulating molecules on the APC and T lymphocytes are necessary for activation of T cells. CD4 + cells differentiate into proinflammatory cells (CD4 + Th1) or antiinflammatory (CD4 + Th2) cells. Proinflammatory cells (Th1) secrete cytokines such as TNF-a or -b or IFN-g. The result is activation of various process, that cause injury to myelin or oligodendrocytes. Antibody-mediated injury may be cell dependent or occur via complement activation. Cell-mediated injury induces damage by further release of proinflammatory cytokines. Binding between FAS-ligand and FAS or binding of ab crystallin will result in apoptosis or programmed cell death. Macrophages induce myelin injury by phagocytosis and secretion of toxic substances, such as proteases, nitric oxide, oxygen radicals, and proinflammatory cytokines. Apoptosis may occur via the FAS-ligand interaction.

In some cases, cytotoxic CD8 + autoreactive T cells may be the primary cause of injury by binding class I MHC antigens on oligodendrocytes. They may also bind via FAS and induce apoptosis. In addition, these cells may release perforins, which create membrane pores and kill cells. Finally, other factors may lead to injury of the oligodendroglia, resulting in ''dying back oligodendrogliopathy.'' The result is varying degrees of demyelination and axonal destruction.

Even as some areas are damaged, others are in various stages of repair. An antiinflammatory process activated via the CD4 Th2 cells, which secrete cytokines such as IL-4, -10, and -13, decreases inflammation and downregulates the immune response. This process occurs simultaneous to the inflammatory response.

Thinly myelinated axons in pathologic specimens indicate that remyelination occurs in patients with MS. Repair likely begins with resolution of inflammation and edema. New sodium channels may develop in a demyelinated axon to allow for propagation of active potential. It is not known if these sodium channels develop from the neuron or surrounding glial cells. Oligodendroglia progenitors capable of proliferation have been identified but the specific role of these cells is not clear. It is known that remyelination can occur if inflammation is controlled.

The final result of this inflammatory process, irreversible axonal injury, is known to occur early in the disease. These findings suggest that early intervention of the disease course, which prevents or decreases inflammation, may prevent axonal injury and allow for remyelination. Multiple potential sites for therapeutic interventions can be considered including blockage of adhesion or co stimulating molecules, cytokine therapy, or modulation of the T cells via vaccination.

Pathology sections of the brain in individuals with MS reveal well-demarcated lesions or plaques that appear pink or gray. Microscopically, the lesions are characterized by inflammation, demyelination, or gliosis. Inflammatory lesions have both perivascular and leptomeningeal infiltration of lymphocytes, monocytes, and macrophages. Histopathologic studies show that macrophages and CD4 + T cells are the most prominent cell types within lesions. There are fewer B cells and plasma cells. Lesions can be further characterized as active (acute), chronic active, or chronic inactive. In the acute lesion, perivascular and parenchymal infiltration with mononuclear cells, such as T cells and macrophages, exists. Cells are mostly large, round, and lipid-laden macrophages. There are variable numbers of CD4 and CD8 cells present. MHC class II positive cells are abundant. Similar findings are seen in ADEM and animal models that have T cellmediated immune responses. In these cases, the demyelination that occurs with MS-type plaques is not present. This implies that there must be another factor present for demyelination to occur. Chronic active plaques have MHC class II cells and lipid-laden macrophages at the border of the lesion but not centrally. Chronic inactive lesions have few MHC class II-positive cells and are hypocellular. Recently evidence indicates that the pathologic process may vary between individuals. Lucchinetti and Lassmann described different types of pathological appearances based on immunohistochemical studies. The first type shows areas of demyelination with no oligodendroglia loss. There is local deposition of demyelinating antibodies and complement activation. The preserved oligodendroglia cells favor remyelination and recovery. A second type has demyelination; however, there is destruction and loss of oligodendroglia cells with the presence of T cells and macrophages in these areas. Local precipitation of antibody and complement is not evident. A third type involves primary demyelination and a gradient loss of oligodendroglia cells toward the center of an inactive plaque. In inactive plaques there is profound oligodendroglia loss. A fourth type describes primary oligodendroglia destruction in white matter near the plaque and resultant secondary demyelination. A fifth type describes demyelination with profound loss of axons, oligodendrocytes, and astrocytes. This is not likely to be due to different stages of the disease since individuals tend to have similar patterns of pathologic changes throughout the brain. Rather, the types of injuries may be the result of different immunologic mechanisms that occur between patients and not within a patient.

The irreversible disability of MS has been attributed to axonal injury, which is evident in autopsy specimens. Charcot recognized degeneration of axons in MS as early as 1877. Recently, axonal transection has been demonstrated even in the early stages of the disease. These findings suggest that accumulating axonal injury from early on may result in progressive disability. Attempts to prevent axonal damage may prevent long-term disability.

Myelin acts as an electrical insulator in the brain and spinal cord. This lipid sheath is produced by oligodendrocytes in the brain and spinal cord. One oligodendrocyte insulates 1-100 axons. The myelin, produced in layers or lamellae, is interrupted by nodes of Ranvier. At the node of Ranvier there is a high density of sodium channels, which are responsible for sodium ion shifts for depolarization. These areas allow for production and propagation of action potentials. Conduction is a saltatory (not a continuous) process. The internodal areas (areas between the nodes of Ranvier under the myelin sheath) have a low proportion of sodium channels and a high proportion of potassium channels, especially in the perinodal region. These potassium channels oppose depolarization. Depolarization produces an electrical charge, which is conducted through the myelinated segment to the next node for depolarization. Myelin increases the speed of conduction and efficiency. With demyelination, slowing of action potentials and conduction block occur. Conduction block prevents propagation of any axon action potential. Sodium channels develop along the demyelinated internodal area as a way to allow for propagation of an action potential, although this is slower. This reorganization of the demyelinated axon results in a higher than normal density of sodium in demyelinated regions. Other factors may interfere with conduction, such as circulating immune factors or edema. In addition to reorganization of sodium channels, resolution of edema or clearance of these factors may restore conduction. Synaptic changes and conduction through normal unmyelinated axons may also restore function.

It is known that small changes in temperature and electrolytes can produce conduction block in demyelinated axons. Patients' symptoms may recur when they have an elevated body temperature as a result of illness or increased environmental temperature. Uthoff's phenomenon is one of the best known of these phenomena. With elevation of body temperature, such as during exercise, individuals develop decreased visual acuity in an eye previously affected by optic neuritis. Symptoms resolve when body temperature returns to normal. Trains of impulses can also block propagation of action potentials by prolongation of the refractory periodFthe time during which a neuron cannot depolarize. Clinically, this occurs as patients complain of fatigability of muscle strength with repetitive use of any extremity, such as occurs during walking. It is possible that modification of the sodium and potassium channels in demyelinated neurons may result in improvement in clinical symptoms.4-Aminopyridine, a potassium channel blocker, is a drug that improves symptoms for patients with MS, especially those who are heat sensitive. Currently, it is not a Federal Drug Administration (FDA)approved drug, but further research into modification of sodium and potassium channels may lead to therapies, that provide improved conduction in demyelinated axons.

Paroxysmal symptoms of MS are a unique feature of the disease that have their basis in the physiology of demyelinated axons. These symptoms include episodes of recurrent hemibody sensory symptoms, paroxysmal dysarthria, and paroxysmal pain such as trigeminal neuralgia. These phenomena may be a result of ephaptic transmission, which occurs when adjacent demyelinated axons communicate in a lateral fashion and result in recurrent abnormal stimuli. Lhermitte's phenomena is a transient electric shock-like sensation in the spine and/or extremities believed to be due to increased mechanosensitivity of demyelinated axons in the spinal cord and it results when neck flexion causes mechanical changes in the spinal cord.

The clinical features of MS are based on the location of lesions rather than the severity of these lesions. Lesions must occur in eloquent areas to produce symptoms. Many lesions occur in areas that are not clinically recognized as symptomatic, including periventricular white matter lesions identified near the lateral ventricles. A relapse of MS is defined as an exacerbation or clinical worsening of neurologic signs and symptoms that persists for weeks to months. This is followed by a period of remission. Symptoms must be present for at least 24 hr to be considered a relapse, but generally they are present longer. Most common are sensory symptoms. They are often the earliest symptoms and occasional are peculiar in distribution. In addition, sensory symptoms may not have objective findings; thus, they are ascribed to other causes such as stress. Patients often complain of ''numbness,'' but they are often experiencing positive sensory phenomena such as tingling or dysesthesias. The ability to detect vibration in the extremities is often decreased and identified by neurologic examinations early in the disease. Often, the sensory symptoms of MS are due to lesions of the posterior columns rather than the spinothalamic tracts; however, decreased pinprick and temperature sensation can occur. Lhermitte's phenomenon is a sensory symptom in which patients experience sudden, brief electrical sensations along the spine or in the extremities. Less commonly, a radicular pattern of pain may occur and is likely due to demyelination of the sensory root entry zone. Lancinating neuralgias or dysesthesias are not uncommon. A ''useless hand'' develops when there is sensory disruption in the sensory spinal tracts that affects vibration, two-point discrimination, and proprioception. Often, this occurs as a result of a high cervical spinal cord lesion of the posterior columns or in the medial lemniscus system of the brain stem. Although strength is preserved, the hand is difficult to manipulate for tasks because of the sensory disruption. This may occur in other spinal disorders, but when it occurs in young individuals it is most likely due to MS.

Disorders of the visual system are common at the onset of MS. Optic neuritis results in acute or subacute monocular loss of vision. Patients complain of blurred vision or dimming of vision, often associated with photophobia and pain that increases with eye movement. Examination often discloses decreased visual acuity and central scotoma of visual loss. The optic nerve head may appear swollen, with hemorrhages or exudate (papillitis), or may be normal appearing (retrobulbar neuritis) by funduscopic examination. Color vision is often affected and can easily be tested by asking a patient view a red object with each eye separately and compare the difference of appearance. An afferent pupillary defect, elicited by shining a bright light on each pupil, may demonstrate delay of pupillary response or dilatation when the light is brought to the affected eye. Often, visual acuity returns to normal within several weeks. Later, optic atrophy may be detected as a pale optic nerve head evident by funduscopic examination. Other types of visual field defects have been described, including bilateral homonymous hemianopia and quadrantanopias, indicative of lesions more posterior in the visual system. Although optic neuritis is commonly associated with MS, other conditions including systemic lupus erythematosus or sarcoidosis must be considered.

Extraocular movement disorders are also relatively common. Examination will often show horizontal nystagmus, which is asymptomatic. Rotary, upbeating and downbeating nystagmus has also been described. A bilateral internuclear ophthalmoplegia (INO) is a result of a lesion in the brain stem in the medial longitudinal fasciculus. Patients develop failure of the ipsilateral eye to adduct, whereas the contralateral eye develops abducting nystagmus. Patients may be asymptomatic with central gaze, but with horizontal gaze they develop diplopia or oscillopsia, a sense of movement of images. The INO may be bilateral or unilateral. Incomplete INO is frequent, detected only by slowed adduction or mild abducting nystagmus. A skew deviation occurs when one eye is slightly elevated compared to the other. Sixth nerve palsies resulting in horizontal diplopia occur, although third and fourth cranial neuropathies are rare.

Vertigo may occur with demyelinating lesions in the brain stem. It is often difficult to determine if vertigo is due to a peripheral or central disorder. Other features of brain stem injury may be helpful in defining the cause of vertigo but are not necessary to conclude that vertigo is a result of MS. Although infrequent, hearing loss is known to occur. Dysfunction of the facial nerve develops from a lesion of the seventh nerve in the brain stem or with a subcortical lesion, causing a central or upper motor neuron type of weakness confined to the lower aspect of the face. Myokymia, which is an involuntary wave-like fasciculating movement in the face, also results from demyelination.

Speech abnormalities include scanning dysarthria, in which each word or syllable is given equal emphasis. Other types of dysarthria, including pseudobulbar or nasal speech, are less common. Symptoms due to cortical dysfunctions, such as aphasias or agnosias, are not typical of MS. Seizures are rare and tend to occur later in the disease. Cerebellar findings are not common early in the disease, but with progression ataxia, dysmetria, intention tremor, and dysdiadochokinesias may all occur.

Cognitive dysfunction is estimated to occur in: 15-50% of all patients with evidence of neuropsychological dysfunction. This aspect of the disease can be very mild to extremely severe with profound dementia. The most common features of cognitive dysfunction include difficulties with recent memory, sustained attention, verbal fluency, conceptual reasoning, and visualspatial perception as determined by neuropsychological testing. These difficulties are not easily defined by simple procedures in the clinic, such as the Mini-Mental status examination. The severity of physical disease does not correlate well with cognitive dysfunction. Cognitive difficulties are significantly disabling and secondary to fatigue, which is the most likely cause of patients discontinuing to work. Depression is very common and may interfere with cognitive function. Euphoria, when present, is associated with significant cognitive difficulties or subcortical forebrain lesions.

Bladder dysfunction, although unusual at onset, is common with progressive disease. Symptoms include frequency, urgency, and incontinence. These symptoms are a result of a failure to store or a failure to empty the bladder. With failure to store, the bladder wall is sensitive and expels small amounts of urine unexpectedly due to bladder wall contractions. With failure to store, the detrusor muscle is weak and urine difficult to expel. Incontinence occurs with overflow of a full bladder. Often, patients have a combination of these problems, referred to as detrusor dyssynergia. Bladder wall contraction occurs simultaneously to closure of the external urethral sphincter and prevents emptying of the bladder. With long-term retention, vesicular ureteral reflux may occur along with hydronephrosis and renal failure. Bowel dysfunction includes constipation, bowel urgency, or incontinence. In an attempt to control bladder symptoms, many patients decrease fluid intake, which worsens constipation. Sexual dysfunction is common and is likely a result of both physiologic and psychosocial factors. Male sexual dysfunction, which has been studied more extensively, includes erectile dysfunction, decreased sensation, and decreased libido resulting in an inability to have erections or ejaculate. Female patients experience decreased sensation, decreased or absent orgasm, decreased arousal, and vaginal dryness.

One of the early manifestations of MS may be transverse myelitis. Patients develop acute or subacute motor and sensory symptoms in the lower extremities extending into the thorax with a definable sensory level. Transverse myelitis may represent the first episode of MS or remain as a monosymptomatic illness, similar to optic neuritis. Para-, hemi-, or quadriplegia may develop during exacerbations. With progressive disease, patients develop a myelopathy with progressive weakness in lower extremities, later involving upper extremities. Associated with the weakness is an increase in muscle stretch reflexes and spasticity. Patients experience stiffness or cramping and intermittent spasms. Discomfort or pain may result.

Finally, paroxysmal symptomsFthe stereotypical, repetitive symptoms and signs that occur in clusters, are a unique feature of MS. Patients may develop ''tonic seizures'' in which dystonic posturing of the hand or arm lasts from seconds to minutes. The individual is unable to control the involuntary flexion or stiffness. Other paroxysmal symptoms include transient dysarthria and sensory phenomena. One of the most common paroxysmal symptoms is trigeminal neuralgia, in which patients experience severe lancinating pain in the face on a repetitive basis. Trigeminal neuralgia may occur in individuals without MS, but it tends to occur at a younger age and is more frequently bilateral in individuals with MS.

The diagnosis of MS is based on the clinical features of the illness. There is no one definitive test for MS. Signs and symptoms define lesions that develop over time (at least 1 month apart) and space (different areas of the central nervous system). Most symptoms tend to develop over several days and then persist for several weeks to months, with improvement and in many cases return to normal. The neurologic examination generally provides objective evidence of the patient's symptoms, however, sensory symptoms may be entirely subjective. Paraclinical data, which include magnetic resonance imaging (MRI), cerebrospinal fluid (CSF), and evoked potentials (EPs), are used to confirm or dispute the clinical diagnosis. The most recent criteria were developed by an International panel of experts in the field MS (Table I) , These criteria incorporate MRI as a tool of assessing subclinical disease activity and providing for a diagnosis before a second clinical event. The criteria includes visual evoked potentials as the only form of evoked potentials to support the diagnosis of MS. Although unusual, the paraclinical data can be normal in some patients with the clinical diagnosis of MS.

CSF has been evaluated from diagnostic and research standpoints. Typical CSF findings in patients with MS include less than 20 white blood cells per cubic milliliter. These cells are mostly lymphocytes and occasionally macrophages. Total protein and glucose levels are usually normal; however, protein levels may be slightly elevated but rarely above 100 mg/dl. The abnormalities in CSF are primarily those of immunoglobulin production. Oligoclonal bands (O bands) represent multiple monoclonal globulins that are mostly of the immunoglobulin-G (IgG) type. O bands are determined by agarose electrophoresis or isoelectric focusing and indicate two or more IgG bands in the gamma region. Agarose electrophoresis is less sensitive but currently more commonly performed. Once O bands are present, they persist indefinitely. There is a low false-positive rate of approximately 4 or 5%. The presence of O bands may be a predictor of the chances of developing clinically definite MS in those indivi-duals with monosymptomatic disease. Patients with O bands in the CSF are more likely to have a confirmed diagnosis of clinically definite MS. Other measures of CSF IgG production include the IgG synthesis rate and the IgG index, which are based on comparison of albumin and immunoglobulin production in the CSF to serum. These measures are considered less specific and sensitive than oligoclonal bands, but they are useful in indicating immune abnormalities and confirming the clinical diagnosis.

Because CSF is more difficult to obtain, other markers for disease activity have been pursued. Urine is an easily accessible fluid, although volume, collection timing, and infections may influence results. Myelin basic protein-like (MBP-L) is smaller than MBP found in the CSF. It has a cryptic epitope that is not exposed in central nervous system myelinFpossibly a small peptide. MBP-L fluctuates independent of acute relapses; however, a sustained increase is present in patients with secondary progressive MS. Levels were also elevated in those individuals with relapsingremitting MS who went on to develop secondary progressive MS. There are currently no markers in the blood that are used for diagnosis of MS. Markers that have been considered include circulating adhesion molecules, antibodies, cell subpopulation, cytokines, and cytokine receptors. 

Evoked potentials were more frequently used in the diagnosis of MS prior to the advent of MRI. The data are generated by presenting repeated stimuli and recording a wave form or EP from scalp surface electrodes. An alternating checkerboard pattern is used as a visual stimuli for visual EP, repeated auditory clicks are used for brain stem auditory EP, and repeated electrical sensory stimulation is used for tibial and somatosensory EP. As a result of repeated stimulation, the EP has a defined latency and amplitude. Based on standards established in each laboratory, a prolongation of the latency of these responses suggests that demyelination has occurred. A loss of amplitude of those responses is abnormal but not necessarily due to demyelination. These studies are nonspecific and are most helpful in confirming a suspicious clinical finding. For example, a distant history of unusual symptoms suggestive of optic neuritis may be confirmed by a prolonged visual evoked response recorded from stimulation of one eye. Confirmed clinical findings do not need to be further assessed with EPs since additional information is not gathered. Currently, EPs are not used to define prognosis or as surrogate markers of disease activity in clinical trials.

Magnetic resonance imaging was first used in 1981 to study patients with MS. The technique was rapidly accepted in the clinical realm. Images are generated as a result of energy release from protons (positively charged hydrogen nuclei) that have been aligned in the axis of a strong magnet. Water, lipids, and other molecules contain hydrogen atoms, which spin and precess around the main axis. This axis is referred to a magnetization vector. Radio frequency pulses cause the protons to rotate and spin away from the main axis. Once the radio frequency pulse is removed, a signal is induced as the protons return to their original rotation. The signal decays over time and is referred to a longitudinal decay (T1) and transverse relaxation (T2) time. T1 and T2 times are the result of the environment in which these proteins exist (e.g., CSF protons require a longer time to return to equilibrium). The radio frequency pulses can be given at different times and for different lengths of time to generate different types of images that are ''weighted'' toward T1 or T2. This weighting is based on repetition time (TR) or time between pulses and echo time (TE), the time to generate the echo. T1 images have both short TE and TR, whereas T2 images have both long TE and TR. CSF is white in T2-weighted images, as are demyelinating lesions of MS (Fig. 2) . On T1-weighted images some chronic lesions appear as dark areas or ''black holes,'' which indicate tissue destruction and probable axonal loss. Newer techniques, such as fluid-attenuated inversion recovery imaging, cancel the signal from CSF, and as a result demyelinating periventricular lesions are more easily detected (Fig. 3) . Gadolinium, a rare element with paramagnetic substance, is given intravenously to provide contrast enhancement of areas of breakdown of the blood-brain barrier. Because gadolinium shortens the T1 and T2 relaxation time, images appear bright where the blood-brain barrier is disrupted. This enhancement, which is the earliest standard MRI evidence of a newly developing MS lesion, indicates acute inflammation and often persists 2-6 weeks in areas of demyelination.

In general, the lesions of MS are ovoid or round and located adjacent to the body or temporal horn of the ventricles, in the corpus callosum or infratentorial or cortical-subcortical areas. Size ranges from a few millimeters to larger confluent areas. Lesions change in size over time and may disappear, however, often an abnormality will persist on T2-weighted images. The white matter may appear diffusely abnormal (i.e., ''dirty white matter''). Cortical lesions are present pathologically but more difficult to detect with MRI. New lesions or enlargement of old lesions occur while other lesions are shrinking. Spinal cord lesions are detected most often in the cervical region. The spinal cord may appear swollen during the acute phase and may be enhanced with use of gadolinium. Optic nerve abnormalities are visualized with special techniques to suppress signal from orbital fat.

Because of the frequency of nonspecific white matter changes in MRI, various criteria have been suggested to define when brain MRI abnormalities are consistent with the clinical diagnosis of MS. One frequently used set of criteria defines significant findings as three or more lesions, that are equal to or greater than 3 mm, with at least one located in periventricular or infratentorial areas. At least 90% of patients with clinically definite MS have MRI abnormalities. Other explanations for white matter abnormalities exist and include patchy white matter abnormalities related to hypertension or diabetes mellitus. Lacunar lesions due to strokes appear isointense to CSF because of complete tissue destruction, which is not typical of MS lesions. Other individuals with risk for cerebrovascular disease may have incidental lesions scattered in the deep white matter. Lesions seen with systemic lupus erythematosus are also located in the deep white matter but are not typically periventricular. Neurosarcoidosis may cause white matter abnormalities but frequently has associated meningeal enhancement due to leptomeningitis. ADEM may appear identical to MS. Lesions tend to resolve and do not recur. Gliomas may appear as solitary lesions, as may ''pseudotumor'' lesions of MS. Follow-up MRI may be definitive, although biopsy may be necessary to distinguish the two. Finally, inherited disorders of myelin, the leukodystrophies, demonstrate symmetric confluent rather than patchy, discrete lesions. A clinical history and examination are most helpful in providing alternate explanations for these abnormalities.

MRI has provided much information about the underlying pathophysiology of MS. Serial imaging has demonstrated that white matter lesions are present even when individuals are not clinically aware of disease activity. This is not a consistent process and varies from month to month, however, the frequency of subclinical lesions may be 5-10 times greater than clinical disease. Clinically evident lesions tend to be present in the brain stem and spinal cord. Subclinical lesions in the cerebrum tend to increase with clinical events. The extent of lesions present on T2 scan does not correlate well with the clinical examination, other than a possible correlation with cognitive dysfunction. However, an increase in the extent of lesions over time correlates with increasing physical disability. The number and area of contrast-enhancing lesions does not correlate with disability. In primary progressive MS, there are often very few lesions present on T2weighted images, compared to relapsing-remitting or secondary progressive MS in which multiple new and 

enhancing lesions tend to develop over time. This may indicate a pathophysiologic difference in disease type. MRI also has a predictive value for the diagnosis of MS in individuals who have had monosymptomatic disease, such as transverse myelitis or optic neuritis. The risk for an eventual diagnosis of clinically definite MS is higher in those individuals with abnormal brain MRI. MRI has been used as a tool in the clinical trial realm, allowing for a shorter clinical trial because it is a surrogate marker for disease activity. This becomes increasingly important as the partially effective therapies available will need to be incorporated into clinical trials of new agents, thus requiring more patients in order to prove efficacy. Problematic in the use of MRI has been clinical trials showing an effect on the clinical or MRI aspect but not vice versa. This apparent mismatch of data will need to be clarified.

Newer techniques add to our understanding of why T2-weighted images may not correlate well with clinical disability. Magnetization transfer imaging (MTI) relies on a different relaxation time of protons bound to macromolecules versus that of those protons that are freely moving in water. The normal appearing white matter of T2 weighted scans is abnormal when assessed with MTI, implying a more diffuse process than demonstrated by conventional T2 images. Magnetic resonance spectroscopy (MRS) uses MRI to generate a spectra of hydrogen or high energy phosphorus-containing metabolites. The spectra is used to define pathology of lesions, including tumors and demyelination. The spectra reveal major resonances from choline, creatine and phosphocreatine, and N-acetylaspartate (NAA). Choline is present in membranes and also present with increased myelin breakdown products. Creatine and phosphocreatine tend to be stable in MS other than acute lesion. NAA is present only in neurons and neuronal processes and can be used as a specific axonal marker in white matter. Decreased NAA is indicative of axonal pathology. MRS has shown a decreased NAA concentration throughout the brain of individuals with MS, implying diffuse injury beyond the site of lesions detected by routine imaging techniques.

Brain atrophy documented by MRI shows volume loss around the third and lateral ventricles and decreased corpus callosum area and brain width. Atrophy has been documented early in the course of the disease, before significant clinical disability, and is likely another indicator of underlying axonal damage.

Thus, standard and newer MRI techniques have shown that MS can be a subclinical process resulting in increasing MRI burden of disease. Findings also support the hypothesis that axonal injury occurs early in the course of the disease and may be more diffuse than previously thought.

Prototypic MS is one of a spectrum of inflammatory demyelinating diseases. This includes acute MS (Marburg variant), Balo's concentric sclerosis, neuromyelitis optica (Devic's disease), and ADEM. Acute MS presents as a fulminant disease that causes severe disability shortly after onset and often death within 1 year. Lesions are more destructive than those of typical MS with axonal destruction and neurosis. Age of lesions is mixed, suggesting that disease is present prior to the clinical diagnosis. Balo's concentric sclerosis is another acute illness that has bands of demyelination alternating with preserved myelin areas. The cerebellum, brain stem, optic chiasm, and spinal cord are often spared. Devic's disease or neuromyelitis optica is defined by optic neuritis and myelopathy occurring together or within a short period of time. Pathologically, necrosis has been evident in both optic nerves and spinal cord, probably as a result of ischemia from swollen tissues. ADEM is a polysymptomatic disease that occurs after upper respiratory infection or other viral infection or following immunization. The disease occurs more commonly in children than in adults and includes demyelination in multiple areas, including brain stem, spinal cord, optic nerves, cerebrum, and cerebellum. Patients may have associated febrile illness and can become comatose in rare cases. The percentage of patients that ultimately have a diagnosis of MS is low (i.e., 5%), but initial presentations, especially if not fulminant, can be confused with the first event of MS. Pathologically, there is infiltration of mononuclear cells with limited periventricular demyelination.

Other illnesses that present as a relapsing-remitting type of illness include Behcet's disease, characterized by oral or genital ulcerations, iridocyclitis, meningoencephalitis, and thrombophlebitis. Lyme disease typically has radicular or peripheral nerve involvement but can be mistaken for MS because of its relapsingremitting course and occasionally by its appearance on MRI. Sjogren's syndrome, in which individuals have vasculitis of the skin and peripheral nervous system associated with dry eyes and dry mouth, has also been confused with MS, in part because of MRI abnormalities that may mimic MS. Neurosarcoidosis may be a relapsing-remitting type of illness, but it generally has multiple cranial mononeuropathies. MRI shows leptomeningeal enhancement associated with intracranial disease. Cerebrovascular disease may be confused with MS, especially when interpreting MRI scans. Primary central nervous system vasculitis or systemic lupus erythematosus (SLE) may mimic the disease because of relapsing-remitting-type illnesses and white matter lesions present on MRI. The lesions seen with SLE tend to be subcortical and not periventricular. Vitamin B 12 deficiency remains in the differential of MS; however, it tends to be a progressive-type disease with symmetric findings consistent with myelopathy and peripheral neuropathy. Myasthenia gravis may fluctuate in severity and could be confused with MS, especially when presenting with diplopia. Other bulbar features are uncommon in early MS, and lack of upper motor neuron findings can be helpful in distinguishing this illness. The hereditary dysmyelinating disorders are usually not confused with MS, although with adult onset of progressive myelopathy one must consider illnesses such as adrenolmyeloneuropathy.

Much has been written about the natural history of MS. Because effective therapies will alter the natural history of the disease, this information is invaluable. Many patients expect to have a progressive disease when they are told a diagnosis of MS. In reality, 50% of patients will be walking without assistance 15 years after the diagnosis. As mentioned previously, the majority of patients present with relapsing-remitting disease. Approximately one-half of relapsing-remitting patients experience progression. Many features have been assessed as prognostic markers for future outcome, including the extent of disability at 5 years, age, sex, the extent of initial symptoms, complete or partial remission, type of symptoms at onset (e.g., optic neuritis, sensory symptoms, and cerebellar findings), and attack frequency in the first 2 and 5 years. Favorable prognostic factors are outlined in Table II . Because of the unpredictable nature of the disease, no firm predictions for an individual's course can be determined early in the disease. Of all predictors, the extent of disability at 5 years is most reliable, but patients who have a very mild early course may later develop significant disability. Death as a result of a relapse is extremely rare, although it may occur as a complication of the disease, such as pneumonia or suicide.

Advances in biotechnology have had a significant impact on the treatment of MS. For many years, treatment relied on the use of broad-spectrum immunosuppressive agents that had numerous toxicities. Early trials reported success with agents that did not withstand larger or more detailed investigations. Historically, the disease has been difficult to study because of the wide variability in presentation and clinical course. Large numbers of patients are necessary to show a consistent reproducible response from a drug. The gold standard for measuring disease activity has been the Kurtzke Expanded Disability Scale (EDSS). This 10-point scale, with half-step gradients, measures physical disability. Unfortunately, it is not a linear scale and is heavily weighted toward gait, especially in the middle range of the scale. Newer measures of disability include the Functional Composite, which evaluates gait (25-ft timed walk), upper extremity function (9-hole peg test), and cognitive function (Paced Auditory Serial Addition Test). MRI is used as a surrogate marker for disease activity.

Genetic engineering has led to the manufacture of compounds such as interferon-b (IFN-b) , which is where produced by Escherichia coli or mammalian ovarian cells after gene insertion. Copaxone (glatiramer acetate) is a synthetic compound made of four amino acids. These agents allow for selective immunomodulation and thus lower toxicity. There is conclusive evidence from large-scale trials that these agents are partially effective in the treatment of MS. IFN-b-1b (Betaseron) was the first of these agents to be assessed. The drug was shown to effectively decrease the risk of exacerbation of MS and had the effect of slowing accumulation of new lesions on MRI. Although the drug did not show an effect on slowing progression of disease, as measured by the EDSS, the effect on MRI led many to believe that the long-term outcome of a patient treated with this will be better than the expected natural history. IFN-b-1a (Avonex) was the second agent to be approved by the FDA. This drug has a similar effect on decreasing the rate of relapse. The primary end point of the clinical trial was efficacy in slowing disability as measured by the EDSS, and this drug has the unique feature of FDA approval for that indication. Copaxone was initially investigated as a potential agent to induce EAE. Conversely to what was expected in the animal model, there appeared to be a protective effect, which led to additional clinical trials. Copaxone decreases the risk of a relapse and has favorable effects on MRI. Currently, it is difficult to argue that one of these agents is superior to the others for treatment of relapsing-remitting MS. Fortunately, it allows for patients to have an option. Worldwide use and access are limited by the high cost ($12,000 per year) and administration (intramuscular or subcutaneous injections). The National Multiple Sclerosis Society has issued a recommendation advocating the use of these drugs early in the course of the disease based on increasing evidence that early treatment is likely beneficial in decreasing the inflammatory phase of the disease and preventing axonal injury. Recently, trials of secondary progressive MS have found mixed results with use of beta-interferons. Mitoxantrone (Novantrone) has received FDA approval in the United States for treatment of secondary progressive MS. This immunosuppressive agent was shown to be effective in European studies in slowing progression of individuals with secondary progressive disease or relapsing-remitting disease unresponsive to other therapies.

Future clinical trials will likely lack a placebo group because it is unethical to leave a patient untreated when partially effective therapies are available. As a result, larger and lengthier clinical trials will be necessary to show an effect of newer agents. Surrogate markers for disease activity, including MRI, will be used to assess the utility of drugs prior to large phase 3 trials needed to show clinical efficacy. As our understanding of the pathological processes of the disease increases, it is possible that different therapies will be indicated for different types of MS. For example, in individuals with a notable inflammatory component as determined by MRI or an other tool, use of immunomodulator therapies that have a specific effect on inflammatory aspect of the disease may be most beneficial. In other cases in which little inflammatory disease appears evident, growth factors or other means to stimulate regenesis of cell life may be more appropriate. In cases in which drugs are not shown to be efficacious for MS, the understanding of the pathophysiology of MS increases and thus the trials cannot be considered failures. Finally, until the cause of the disease is found, a cure is not likely. Fortunately, advances in understanding the disease process have been exponential in recent years, allowing hope for control, if not cure, for this disease in the near future. 

The contribution of magnetic resonance imaging to the diagnosis of multiple sclerosis

Distinct patterns of multiple sclerosis pathology indicate heterogeneity on pathogenesis

Recommended Diagnostic Criteria for Multiple Sclerosis: Guidelines from the International Panel on the Diagnosis of Multiple Sclerosis

Progress in determining the causes and treatment of multiple sclerosis

Diagnosis of Multiple Sclerosis

Demyelinating diseasesFNew pathological insights, new therapeutic targets

The natural history of multiple sclerosis: Update